PTO/SB/08A (10/01) (modified)
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO						ication Number	10/667,966				
	-0	`			Filing	g Date	September 23, 2003				
			ON DISCLOS		First	Named Inventor	Dong XIE et al.				
STATEMENT BY APPLICANT					Art Unit		1645 1648 HOY 2 5 7006 W				
	(us	e as many	y sḥeets as necessal	(Y)	Exan	niner Name	Not yet assigned PARIST				
Sheet		1	of 2		Attor	rney Docket Number	63024.000	002	maney?	*/	
Sheet 1 of 2 Attorney Docket Number 63024.000002 TATRACE U.S. PATENT DOCUMENTS											
	T	200		U.S. FAI	ENT	DOCOMENTS			olumns, Lines,		
*Examiner trittals	Cite No.		DOCUMENT NUMBER Number - Kind Code (if known)		Date	Name of Patentee or Applicant of Cited Document		Where Relevant Passages or Relevant Figures Appear			
7	1.	US- 3,719,667		03-06-1973		GUTOWSKI					
a	2.	US-	US- 3,840,556		974	KUKOLJA		-			
	3.	US-	US- 5,612,034		997	POULETTY et al.					
	4.	US-	US- 5,840,697		998	BLONDELLE et al.					
	5.	US-	6,268,479 B1	07-31-20		STERN et al.	STERN et al.				
¥	6.	US-	6,281,331 B1	08-28-20	001	KANG et al.					
<u> </u>	!	US-					· · · · · · · · · · · · · · · · · ·				
<u> </u>		US-		<u> </u>				·			
		US-		<u> </u>							
		US-									
<u> </u>	!	US-									
	$\perp \!\!\! \perp \!\!\! \perp \!\!\! \perp \!\!\! \perp$	US-	-								
<u> </u>	$\perp \!\!\! \perp \!\!\!\! \perp \!\!\! \perp \!\!\!\! \perp \!\!\! \perp \!\!\! \perp \!\!\!\! \perp \!\!\!\!\! \perp \!\!\!\!\! \perp \!\!\!\! \perp \!\!\!\!\! \perp \!\!\!\!\! \perp \!\!\!\!\! \perp \!\!\!\!\!\!$	US-		<u> </u>	<u> </u>						
<u> </u>	!	US-		<u> </u>							
		-	FC	OREIGN P	ATEN	NT DOCUMENTS	ī				
l		FOREIGN	PATENT DOCUMENT								
		Country	Number - Kind Code (if known)				Pages, Co	olumns, Lines,	TRANSL	ATION	
*Examiner Initial	Cite No.	Code:		Publication D MM-DD-YYY	1	Name of Patentee or Applicant of Cited Document	Where Rela	evant Passages Figures Appear	YES	NO	
7	7.	PCT	WO 00/69902	11-23-200		BRIDON et al.					
	8.	PCT	WO 00/70665	11-23-200	00 B	BRIDON et al.					
1	9.	PCT	WO 00/69911	11-23-200	00 B	BRIDON et al.	<u> </u>				
	1						1				
	1						†				
								,			
FXAN	MNER	SIGNATUR	DE /		7,	DATE CONSIDERED (1 1		L	<u></u>	
10 16 06											
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											

خمست	,	.				U.S. Patent and Tradema	PTO/SB/08A (10/ rk Office; U.S. DEPARTMENT OF	/01) (mr = COM)	odified) MERCE		
Substitute for form 1449A/PTO INFORMATION DISCLOSURE						Application Number	10/667,966				
						Filing Date	September 23, 2003				
					=	First Named Inventor	Dong XIE et al.				
51/					APPLICANT	Art Unit					
	(US	30 as ma	∄Ny Si	heets	as necessary)	Examiner Name	Not yet assigned PAR	س			
Sheet 2 of 2						Attorney Docket Number	63024.000002				
			ОТН	ER C	OCUMENTS - NOI	N-PATENT LITERATURE	DOCUMENTS				
"Examiner Initiats	Cite No.			clude na	ame of the author (in CAPITAL book, magazine, journal, serial	L LETTERS), title of the article (when all, symposium, catalog, etc.), date, pag	appropriate), title of the ge(s), volume-issue	TRANS	SLATION		
Institutes	└ ─	_			number(s), publish	ner, city and/or country where publishe	ed	YES	NO		
8	10.		T.W. GREEN, "Protection for the Carboxyl Group," Chapter 5, Protective Groups in Organic Synthesis, published by John Wiley & Sons, New York, USA, 1981, pp. 152-192.								
	11.	CRE Stru	CREAMER et al., "a-Helix-Forming Propensities in Peptides and Proteins," PROTEINS: Structure, Function, and Genetics 19:85-97 (1994), Wiley-Liss, Inc.								
	12.	attra	CHAN et al., "Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target," Proc. Natl. Acad. Sci. USA, vol. 95, pp. 15613-15617, December 1998, The National Academy of Sciences								
	13.	core Proc	MALASHKEVICH et al., "Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: Conserved helical interactions underlie the broad inhibitory activity of gp41 peptides," Proc. Natl. Acad. Sci USA, vol. 95, pp 9134-9139, August 1998, The National Academy of Sciences								
	14.	imm	WILD et al., "Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection," Proc. Natl. Acad. Sci. USA, vol. 91, pp. 9770-9774, October 1994, The National Academy of Sciences								
1	15.	albu	STEHLE et al., "The loading rate determines tumor targeting properties of methotrexate- albumin conjugates in rats," Anti-Cancer Drugs, 1997, vol. 8, pp. 677-685, Rapid Science Publishers								
			<u> </u>								

DATE CONSIDERED 10 16 00 *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER SIGNATURE